Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: a phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy.
Hubner, Richard A Chen, L Siveke, J Li, C Bodoky, G Dean, A Shan, Y Jameson, G Macarulla, T Lee, K
Hubner, Richard A
Chen, L
Siveke, J
Li, C
Bodoky, G
Dean, A
Shan, Y
Jameson, G
Macarulla, T
Lee, K
Citations
Altmetric:
Abstract
Description
Date
2016-10-01
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: a phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy. 2016, 27(suppl 6):693P Annals of Oncology